super(124)I-L19-SIP for immuno-PET imaging of tumour vasculature and guidance of super(131)I-L19-SIP radioimmunotherapy

Purpose: The human monoclonal antibody (MAb) fragment L19-SIP is directed against extra domain B (ED-B) of fibronectin, a marker of tumour angiogenesis. A clinical radioimmunotherapy (RIT) trial with super(131)I-L19-SIP was recently started. In the present study, after GMP production of super(124)I...

Full description

Saved in:
Bibliographic Details
Published in:European journal of nuclear medicine and molecular imaging 2009-08, Vol.36 (8), p.1235-1244
Main Authors: Tijink, Bernard M, Perk, Lars R, Budde, Marianne, Stigter-van Walsum, Marijke, Visser, Gerard WM, Kloet, Reina W, Dinkelborg, Ludger M, Leemans, CRene, Neri, Dario, Dongen, Guus AMS
Format: Article
Language:English
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Purpose: The human monoclonal antibody (MAb) fragment L19-SIP is directed against extra domain B (ED-B) of fibronectin, a marker of tumour angiogenesis. A clinical radioimmunotherapy (RIT) trial with super(131)I-L19-SIP was recently started. In the present study, after GMP production of super(124)I and efficient production of super(124)I-L19-SIP, we aimed to demonstrate the suitability of super(124)I-L19-SIP immuno-PET for imaging of angiogenesis at early-stage tumour development and as a scouting procedure prior to clinical super(131)I-L19-SIP RIT. Methods: super(124)I was produced in a GMP compliant way via super(124)Te(p,n) super(124) I reaction and using a TERIMO registered module for radioiodine separation. L19-SIP was radioiodinated by using a modified version of the IODO-GEN method. The biodistribution of coinjected super(124)I- and super(131)I-L19-SIP was compared in FaDu xenograft-bearing nude mice, while super(124)I PET images were obtained from mice with tumours of
ISSN:1619-7070
1619-7089
DOI:10.1007/s00259-009-1096-y